

Surveillance of Invasive Pneumococcal Disease and Antimicrobial Resistance in the Adult Population in Ireland

Imelda Vickers¹, Mary Corcoran¹, Martha McElligott¹, Jolita Mereckiene², Margaret Fitzgerald², Stephen Murchan², Suzanne Cotter², Mary Cafferkey^{1,3,4}, Darina O'Flanagan², Robert Cunney^{1,2,4}, Hilary Humphreys^{1,3,5}.

¹Pneumococcal Reference Laboratory, Epidemiology and Molecular Biology Unit EMBU Laboratory, Temple Street Children's University Hospital, Dublin, Ireland. ²Health Protection Surveillance Centre, Dublin.

³Department of Clinical Microbiology, the Royal College of Surgeons in Ireland, Dublin. ⁴Department of Microbiology, Temple Street Children's University Hospital, Dublin.

⁵Department of Microbiology, Beaumont Hospital, Dublin, Ireland.

Presenting Author: Mary Corcoran, marycorcoran@gmail.com, mary.corcoran@cuh.ie




Objectives

- The majority of invasive pneumococcal disease (IPD) infections are caused by a subset of predominant *Streptococcus pneumoniae* serotypes, which are included in pneumococcal conjugate vaccines (PCV's) and pneumococcal polysaccharide vaccines (PPV).
- The objective of this study was to assess the serotype distribution and antimicrobial resistance associated with IPD in adults.

Methods

- S. pneumoniae* isolates from sterile sites in adults over 18 years of age and older were submitted for serotyping using multiplex-PCR (Figure 1) and serological co-agglutination.
- Susceptibilities to penicillin, cefotaxime and erythromycin were determined using the E-test method and CLSI guidelines for meningitis.

Figure 1: Multiplex PCR for *S. pneumoniae*



Vickers et al., 2011.EJCMID. 30(3): p. 447-453.

Results

- There was a total of 1852 IPD isolates between July 2007 and June 2014 from adults ≥ 18 years of age (230-298/year).
- The proportion of IPD isolates covered by PCV7, the additional serotypes in PCV13 but not PCV7 (PCV13-7) and PPV23 were 27%, 31% and 76%, respectively.
- The five predominant serotypes (38% of total) were 7F, 19A, 22F, 14 and 8, all in PPV vaccine, 7F and 19A (PCV13 and PPV) & 14 which is included in (PCV7, PCV13, PPV).
- See **table 1** for details of serotypes in the PPV and PCV's.

| Table 1 | Serotypes covered | Recommendation |
|---------|--|---|
| PCV7 | 4, 6B, 9V, 18C, 19F, 23F | Routine infants schedule and catch-up for children < 2 years – Sept. 2008 |
| PCV13 | PCV7 + 1, 3, 5, 7F, 6A, 19A | Routine infant schedule – Dec. 2010 |
| PPV23 | 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F. | For adults ≥ 65 years of age and patients who may be immunocompromised. <u>Underlined serotypes in PPV only</u> (others are in both PCV and PPV). |

Figure 2: The distribution of IPDs according to serotype grouping, 2007-14





Figure 3: The Percentage of IPD isolates that were PNSP and the incidence rate of IPD, 2007-14.



Distribution of Serotypes

When the results for 2007-08 were compared to 2013-14, there was:

- A 50% increase in number of non-PPVs ($p < 0.001$). **Purple line** in **Figure 2**.
- 26% decline in the overall number of PPV's. (data not shown)
- The group of serotypes covered by PPV only (underlined in **Table 1**) increased over this time. **Red line** in **Figure 2**.
- PCV7 associated serotypes fell by 83% over the same period ($p < 0.001$). **Blue line** in **Figure 2**.
- The additional serotypes in PCV13-7 serotypes increased initially to a peak in 2011-12 ($n=95$) but fell by 10% in 2013-14 ($n=85$). **Green line** in **Figure 2**.

Acknowledgements: We would like to thank the clinical laboratories that submitted isolates. This project is funded by the Royal College of Surgeons Ireland, Temple Street Children's University Hospital, Health Protection Surveillance Centre and Pfizer Ireland.

Antimicrobial Resistance

- The incidence rate of IPD and the percentage of isolates that were penicillin non-susceptible pneumococci (PNSP) increased gradually with age.
- This ranged from 11% of isolates in patients 18-39 years to 29% in patients ≥ 75 years old ($p < 0.001$). See **Figure 3**.
- Reduced susceptibility to cefotaxime and erythromycin was also observed in older patients.

Conclusion

- The potential coverage against IPD in adults provided by PCV7, PCV13 and PPV was 27%, 31% and 76%, respectively.
- The decline in the number of PCV7 and PCV13-7 serotypes indicates that the vaccines offered herd effect immunity.
- However, increased antimicrobial resistance associated with the elderly is of concern.